Cost benefit analysis and the FDA : measuring the costs and benefits of drug approval under the PDUFA I-II : 1998-2005
Year of publication: |
2024
|
---|---|
Authors: | DeCanio, Samuel |
Subject: | Cost benefit analysis | FAERS | FDA | PDUFA | Vioxx | Kosten-Nutzen-Analyse | Cost-benefit analysis | Arzneimittel | Pharmaceuticals | Arzneimittelrecht | Pharmaceutical law | Pharmaindustrie | Pharmaceutical industry |
-
Innovation im Arzneimittelmarkt
Klauber, Jürgen, (2000)
-
Peltzman Revisited : Quantifying 21st Century Opportunity Costs of FDA Regulation
Mulligan, Casey B., (2021)
-
Peltzman Revisited : Quantifying 21st Century Opportunity Costs of FDA Regulation
Mulligan, Casey B., (2021)
- More ...
-
Hayek, ideas, and economic history
DeCanio, Samuel, (2024)
- More ...